MRD's Expanding Role in NPM1-Mutated AML

In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as both a prognostic biomarker and a potential treatment goal for patients with NPM1-mutated acute myeloid leukemia (AML).

Wang explains that robust evidence has established MRD negativity, assessed using highly sensitive quantitative polymerase chain reaction (qPCR) testing for NPM1 mutations, as a strong predictor of outcomes in younger, fit patients receiving intensive chemotherapy. As treatment options continue to expand, investigators are exploring whether this well-validated biomarker can be applied to patients receiving lower-intensity regimens, including combinations incorporating targeted therapies such as menin inhibitors.

Wang notes that MRD status has become an important tool for estimating relapse risk before allogeneic stem cell transplantation, as patients who enter transplant with minimal or undetectable residual disease generally have more favorable outcomes. Advances in transplant techniques have also made allogeneic transplantation feasible for a broader population of older adults, further increasing the clinical relevance of MRD testing in treatment planning.

Looking ahead, Wang discusses how MRD is becoming an increasingly important end point in ongoing clinical trials of NPM1-mutated AML. She explains that investigators are evaluating MRD negativity as a biomarker of treatment response across both intensive and lower-intensity therapeutic approaches and are exploring its potential role in guiding long-term management decisions, including the use of transplantation. As these studies mature, MRD may become an increasingly valuable tool for personalizing therapy and optimizing outcomes for patients with NPM1-mutated AML.